Great list Zuess! While not a near term catalyst, since the target audience is someone likely new to CytoDyn, I would include a blurb about the safety profile or leronlimab....no SAEs in over 700 patients to date.....maybe the efficacy results also in this same bullet point.

Not sure if is worth mentioning but the only other thing would be the other possible indications that leronlimab has potential in such as NASH, RA, MS, etc. I know many of these haven’t been ‘officially’ tested yet, but they list NASH in every single PR in the “About CytoDyn” section....so they clearly think it has potential and this is a huge market!